Holsinger Leslie (CIK 0001770821)

Latest company ownership

Role: EVP, Preclinical Development
Shares held
148,080
Last filed at
Jun 8, 2022
Confidence Score
50.0
2025Q4
Confidence Score History
2020Q4 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Jun 6, 2022 Jun 8, 2022 Quince Therapeutics, Inc. EVP, Preclinical Development Sell 36.3 -10,920 -6.87% $31.2K
Dec 14, 2020 Dec 15, 2020 Quince Therapeutics, Inc. President Sell 5.0 -40,000 -30.00% $1.2M